<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Triapine is a potent <z:chebi fb="0" ids="26561">ribonucleotide</z:chebi> reductase (RR) inhibitor that depletes intracellular deoxyribonculeotide pools, especially <z:chebi fb="0" ids="16284">dATP</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>We designed a Phase I trial of Triapine followed by the <z:chebi fb="3" ids="16335">adenosine</z:chebi> analog fludarabine in adults with refractory <z:hpo ids='HP_0002488'>acute leukemias</z:hpo> and aggressive <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Two schedules were examined: (A) Triapine 105 mg/m(2)/day over 4 h followed by fludarabine daily x 5 (24 patients, fludarabine 15-30 mg/m(2)/dose); (B) Triapine 200 mg/m(2) over 24h followed by 5 days of fludarabine 30 mg/m(2)/day (9 patients) </plain></SENT>
<SENT sid="3" pm="."><plain>Complete and partial responses (CR, PR) occurred in Schedule A (5/24, 21%), with CR occurring at the 2 highest fludarabine doses (2/12, 17%) </plain></SENT>
<SENT sid="4" pm="."><plain>In contrast, no CR or PR occurred in Schedule B </plain></SENT>
<SENT sid="5" pm="."><plain>Four of the 5 responses occurred in patients with underlying <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> (4/14, 29%) </plain></SENT>
<SENT sid="6" pm="."><plain>Drug-related toxicities included <z:hpo ids='HP_0001945'>fever</z:hpo> and <z:hpo ids='HP_0001942'>metabolic acidosis</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Triapine 105 mg/m(2) followed by fludarabine 30 mg/m2 daily x 5 is active in refractory <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> and warrants continuing study for patients with aggressive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> </plain></SENT>
</text></document>